Enanta Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery and development of small molecule drugs. The primary focus of the company is on creating innovative treatments for viral infections and liver diseases. Enanta has a proven track record in drug discovery, having developed lead candidates for hepatitis C virus (HCV), respiratory syncytial virus (RSV), and non-alcoholic steatohepatitis (NASH). Its strategic collaboration with major pharmaceutical companies has resulted in the successful commercialization of HCV treatments. The company's pipeline is rich with potential therapies targeting significant global health issues, maintaining a critical role in advancing medical breakthroughs. Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts and operates in a highly competitive biotech sector, where it leverages deep expertise in medicinal chemistry and drug development to address unmet medical needs. Enanta's contribution to antiviral therapies reinforces its significance in the fast-evolving field of biotechnology.